Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYuanyuan ZhengYXYuanyuan XuWHWenfa Huang

Discussion

Loading...

Member takes

Overview

Updated analysis shows CAR T-cell therapy improves progression-free survival in non-Hodgkin lymphoma, indicating a manageable safety profile with cytokine release syndrome.

Key Points

  • CAR T-cell therapy achieved a 77% overall response rate among 32 patients with relapsed non-Hodgkin lymphoma.
  • Patients received infusions ranging from 0.3 to 2.7 million CAR-T cells per kilogram post-chemotherapy.
  • Safety profiling revealed cytokine release syndrome in over half of the treated patients, indicating manageable toxicity.
  • Further validation of this bispecific approach is necessary, particularly regarding its long-term efficacy and safety.

Cite This Study

Zheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d59dhttps://doi.org/10.1182/blood-2025-1946
View Full Paper
Ask AI
Bookmark
Share